BioMarin Pharmaceutical (BMRN) : Sectoral Asset Management Inc scooped up 129,215 additional shares in BioMarin Pharmaceutical during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 1,489,137 shares of BioMarin Pharmaceutical which is valued at $123.2 Million.BioMarin Pharmaceutical makes up approximately 5.97% of Sectoral Asset Management Inc’s portfolio.
Other Hedge Funds, Including , Zacks Investment Management sold out all of its stake in BMRN during the most recent quarter. The investment firm sold 4,188 shares of BMRN which is valued $346,389.Daiwa Securities Group boosted its stake in BMRN in the latest quarter, The investment management firm added 200 additional shares and now holds a total of 3,800 shares of BioMarin Pharmaceutical which is valued at $314,298.Tiaa Cref Investment Management boosted its stake in BMRN in the latest quarter, The investment management firm added 111,026 additional shares and now holds a total of 1,593,769 shares of BioMarin Pharmaceutical which is valued at $128.8 Million. BioMarin Pharmaceutical makes up approx 0.10% of Tiaa Cref Investment Management’s portfolio.
BioMarin Pharmaceutical opened for trading at $88.31 and hit $89.85 on the upside on Wednesday, eventually ending the session at $88.81, with a gain of 0.98% or 0.86 points. The heightened volatility saw the trading volume jump to 10,62,649 shares. Company has a market cap of $14,416 M.
On the company’s financial health, BioMarin Pharmaceutical reported $-0.53 EPS for the quarter, missing the analyst consensus estimate by $ -0.25 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $-0.28. The company had revenue of $236.70 million for the quarter, compared to analysts expectations of $239.85 million. The company’s revenue was up 16.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.43 EPS.
Many Wall Street Analysts have commented on BioMarin Pharmaceutical. Robert W. Baird Upgraded BioMarin Pharmaceutical on Mar 8, 2016 to ” Outperform”, Price Target of the shares are set at $110.Company shares were Reiterated by Stifel on Mar 3, 2016 to “Buy”, Firm has raised the Price Target to $ 107 from a previous price target of $105 .Shares were Reiterated by Wedbush on Feb 29, 2016 to “Neutral” and Lowered the Price Target to $ 105 from a previous price target of $117 .
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha) Naglazyme (galsulfase) Kuvan (sapropterin dihydrochloride) Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States the European Union. Aldurazyme which was developed in collaboration with Genzyme Corporation (Genzyme) was approved for marketing in the United States the European Union and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).